Early-Stage HER2-Positive Breast Cancer Systemic Therapy

Authored by Samantha El Warrak, published on 2026-10-16 00:38:13.0

The algorithm appropriately recognizes paclitaxel-trastuzumab for selected small node-negative tumors and approximately 1 year of HER2-directed therapy. However, the stage II-III pathway omits the current preferred neoadjuvant approach, surgery-based response assessment, and adjuvant trastuzumab emtansine for residual invasive disease. Its stage groupings also oversimplify T1 tumors, particularly T1cN0 and very small T1a lesions.

  1. Newly Diagnosed Early HER2+ Breast Cancer
    A contemporary early-breast-cancer guideline supports the overall diagnostic, staging, and systemic-treatment framework for nonmetastatic HER2-positive disease.
    • Assess Stage & Pathology
      • Stage I (cT1a–b, cN0)
        Guidelines support risk-adapted management of small node-negative tumors, but T1a and T1b should be distinguished. Systemic therapy for T1aN0 disease is individualized, while trastuzumab-based therapy is more commonly recommended for T1b and larger tumors.
        • Upfront Surgery
          Surgery-first management is appropriate for many clinically node-negative T1 tumors, with final pathology guiding adjuvant systemic treatment.
          • Adjuvant TH Indicated?
            • Adjuvant Paclitaxel + Trastuzumab (TH)
              The APT regimen is a widely accepted de-escalated option for selected node-negative HER2-positive tumors, with excellent long-term outcomes. Evidence comes from a prospective single-arm phase II study rather than a randomized comparison.
              • Complete ~1 Year of HER2-Directed Therapy
                • Follow-Up & Surveillance
                  Clinical exam, imaging as indicated
            • Follow-Up & Surveillance
              Clinical exam, imaging as indicated
      • Clinical Stage II–III
        Neoadjuvant systemic therapy is preferred for most node-positive or stage II-III HER2-positive cancers. The node is only partially supported because T1cN0 is generally stage I and may reasonably undergo surgery first.
        • Neoadjuvant T-DXd ×4 → THP ×4 OR TCHP OR AC → THP
          Chemotherapy plus HER2-directed therapy is standard, and adjuvant pertuzumab benefit is concentrated in node-positive disease. This node is incomplete because stage II-III disease is generally treated neoadjuvantly, with postoperative therapy determined by pathologic response.
          • Surgery
            • Pathologic Complete Response (pCR)?
              Pathologic response is prognostic and directly determines postoperative escalation. Residual invasive carcinoma in the breast or nodes was the key KATHERINE eligibility criterion.
              • pCR
                • Continue Trastuzumab ± Pertuzumab to Complete ~1 Year of HER2-Directed Therapy
                  • Follow-Up & Surveillance
                    Clinical exam, imaging as indicated
              • Residual Invasive Disease
                Residual invasive disease after neoadjuvant taxane and trastuzumab-based therapy identifies a high-risk group for postoperative escalation. The established standard is 14 cycles of T-DM1 unless newer jurisdiction-specific guidance has formally replaced it.
                • Prior neoadjuvant regimen?
                  • Prior Taxane + H ± P → Adjuvant T-DXd × up to 14 cycles
                    This is a controversial or evolving node. KATHERINE established T-DM1 as postoperative standard therapy; T-DXd should replace it only where mature DESTINY-Breast05 evidence has resulted in current regulatory approval and guideline adoption.
                    • Follow-Up & Surveillance
                      Clinical exam, imaging as indicated
                  • Prior T-DXd → THP → Individualize Post-Neoadjuvant Therapy
                    • Follow-Up & Surveillance
                      Clinical exam, imaging as indicated
      • Stage I (cT1c, cN0)
        • Surgery*
          *selected high-risk cT1cN0 → neoadjuvant therapy
          • Adjuvant Paclitaxel + Trastuzumab (TH)
            The APT regimen is a widely accepted de-escalated option for selected node-negative HER2-positive tumors, with excellent long-term outcomes. Evidence comes from a prospective single-arm phase II study rather than a randomized comparison.
            • Complete ~1 Year of HER2-Directed Therapy
              • Follow-Up & Surveillance
                Clinical exam, imaging as indicated
  2. If HR+: Add Adjuvant Endocrine Therapy
    Adjuvant endocrine therapy is indicated for hormone-receptor-positive invasive disease regardless of HER2 status and may generally overlap with ongoing HER2-directed therapy. This node should be connected to all hormone-receptor-positive postoperative pathways.
tosprivacy